Biotech is guessing how Vinay Prasad might change the FDA. His research, writing offer clues.

Biotech is guessing how Vinay Prasad might change the FDA. His research, writing offer clues.

Across hundreds of published papers, CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might push for higher standards in the review of medicines under his division's purview.

New CBER Director Vinay Prasad praises evidence, FDA reviewers in first speech to staff

The CBER director sounded very different from his online firebrand persona. He struck a humble, self-deprecating, and even earnest tone in his speech to FDA staff.